Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 8/20 | 0.50 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.44 |
| ▸ | CCR2 | P41597 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7743563 | 0.85 | MCL1 (0.60) | MCL1NOD2NOD1CCR2DAO | |
| SCHEMBL3836440 | 0.81 | ALDH1A1 (0.62) | PLA2G10MCL1NOD2NOD1CCR2 | |
| SCHEMBL6674180 | 0.78 | NOD2 (0.71) | MCL1F10NOD2NOD1ALDH1A1 | |
| SCHEMBL16402064 | 0.77 | PLA2G10 (0.48) | PLA2G10SLC9A1MCL1F10CCR2 | |
| SCHEMBL2323444 | 0.76 | MCL1 (0.71) | PLA2G10SLC9A1MCL1DAOMAPT | |
| SCHEMBL2830160 | 0.75 | PLA2G10 (0.54) | PLA2G10SLC9A1MCL1F10CCR2 | |
| Hydrochloric Acid SCHEMBL28264080 | 0.75 | MCL1 (0.69) | PLA2G10SLC9A1MCL1DAOMAPT | |
| SCHEMBL4103400 | 0.74 | PLA2G10 (0.53) | PLA2G10SLC9A1MCL1F10CCR2 | |
| SCHEMBL7670332 | 0.74 | DAO (0.70) | PLA2G10SLC9A1MCL1F10CCR2 | |
| Hydrochloric Acid SCHEMBL27784064 | 0.74 | PLA2G10 (0.53) | PLA2G10SLC9A1MCL1F10CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | claimed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | claimed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | disclosed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | disclosed |
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-1018878-A4 | NOVEL INDOLECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODSOF INHIBITING CALPAIN | SMITHKLINE BEECHAM CORP (US) | 2001-01-10 | — | — | EP | disclosed |
| EP-1018878-A1 | NOVEL INDOLECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODSOF INHIBITING CALPAIN | SmithKline Beecham Corporation (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998041092-A1 | NOVEL INDOLECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODSOF INHIBITING CALPAIN | SMITHKLINE BEECHAM CORPORATION (US) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | PLA2G10 932/4885SLC9A1 4792/4885MCL1 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.